Activation of hepatic AMPK by 17β-estradiol suppresses both nuclear receptor Nr2c2/TR4 and its downstream lipogenic targets, reduces gluconeogenic genes and improves insulin signaling

Estrogen replacement reduces the frequency of type 2 diabetes (T2D), an effect which involves the suppression of hepatic glucose production. The objective of this study was to identify the hepatic mechanisms involved in the beneficial effects of 17β-estradiol (E2) on insulin sensitivity in mice exposed to long term (10 months) high fat diet (HFD) feeding. E2 treatment in HFD mice led to significant improvements in glycemic control. In the livers from these animals, Western blotting studies showed that E2 treatment led to significant increases in the activation state of the AMP-activated protein kinase (AMPK), in association with reduction of the nuclear receptor Nr2c2/TR4 both mRNA and protein levels, and suppression of downstream lipogenic gene expression. These effects were in parallel with up-regulation of hormone sensitive lipase (lipe) expression by E2. Increased fasting glucose levels following HFD feeding were associated with increases in the expression levels of the gluconeogenic genes, g6pt1 and pyruvate carboxylase, whilst E2 treatment significantly reduced their expression levels. The insulin signaling pathway was studied in the liver after acute insulin intervention. The phosphorylation states of AKT2 and FOXO1 were both decreased in HFD mice, and E2 treatment reversed these changes. In conclusion, E2 treatment reduced body weight and improved glycemic control in association with activation of hepatic AMPK, reduced expression of its downstream target Nr2c2/TR4, and consequent decreases in lipogenic gene expression. Together with increased triglyceride mobilization, these changes paralleled improved hepatic insulin signaling and reduced gluconeogenic gene expression.

[1]  D. Erion,et al.  Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. , 2016, Endocrinology.

[2]  S. Yang,et al.  The effects of vitamin D3 on lipogenesis in the liver and adipose tissue of pregnant rats. , 2015, International journal of molecular medicine.

[3]  Josef Vagner,et al.  Oestrogen receptors interact with the α-catalytic subunit of AMP-activated protein kinase , 2015, Bioscience reports.

[4]  P. Davis,et al.  Overlapping nongenomic and genomic actions of thyroid hormone and steroids , 2015, Best practice & research. Clinical endocrinology & metabolism.

[5]  Jiyeon Lee,et al.  AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response. , 2014, Biochimica et biophysica acta.

[6]  K. Petersen,et al.  The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes , 2014, Nature.

[7]  K. Petersen,et al.  Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance , 2013, Diabetes.

[8]  Siyuan Gao,et al.  Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  Chawnshang Chang,et al.  Metformin Inhibits Nuclear Receptor TR4–Mediated Hepatic Stearoyl-CoA Desaturase 1 Gene Expression With Altered Insulin Sensitivity , 2011, Diabetes.

[10]  A. Hevener,et al.  Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. , 2010, American journal of physiology. Endocrinology and metabolism.

[11]  M. Yoon.  The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. , 2009, Pharmacological research.

[12]  G. Shulman,et al.  Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes , 2009, Proceedings of the National Academy of Sciences.

[13]  Gaochao Zhou,et al.  AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.

[14]  R. Burcelin,et al.  Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. , 2009, Endocrinology.

[15]  K. Dahlman-Wright,et al.  Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. , 2008, American journal of physiology. Endocrinology and metabolism.

[16]  K. Berndt,et al.  The estrogen receptor {alpha}-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms. , 2008, The Journal of endocrinology.

[17]  E. Isenovic,et al.  Insulin signaling in the liver and uterus of ovariectomized rats treated with estradiol , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  H. Saito,et al.  Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women , 2007, Menopause.

[19]  K. Dahlman-Wright,et al.  Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. , 2006, Molecular endocrinology.

[20]  K. Dahlman-Wright,et al.  Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver , 2006, Diabetologia.

[21]  S. Souza,et al.  Estrogen Regulation of Adiposity and Fuel Partitioning , 2005, Journal of Biological Chemistry.

[22]  K. Ho,et al.  Estrogen regulation of growth hormone action. , 2004, Endocrine reviews.

[23]  Kohjiro Ueki,et al.  Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Howard,et al.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial , 2004, Diabetologia.

[25]  Y. Kido,et al.  Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo , 2004, Nature Medicine.

[26]  S. Zolotukhin,et al.  Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[28]  E. Vittinghoff,et al.  Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.

[29]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[30]  C. Sempos,et al.  Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). , 2002, Diabetes care.

[31]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[32]  Hitoshi Shimano,et al.  Identification of Liver X Receptor-Retinoid X Receptor as an Activator of the Sterol Regulatory Element-Binding Protein 1c Gene Promoter , 2001, Molecular and Cellular Biology.

[33]  S. Tsai,et al.  The impact of years since menopause on the development of impaired glucose tolerance. , 2001, Journal of clinical epidemiology.

[34]  J. Flier,et al.  In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. , 2000, Endocrinology.

[35]  D. Hardie,et al.  5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. , 2000, Diabetes.

[36]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[37]  P. Fioretti,et al.  Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.

[38]  M. Laakso,et al.  Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. , 1990, Arteriosclerosis.

[39]  D. Hardie,et al.  Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. , 1988, European journal of biochemistry.

[40]  D. Waxman,et al.  Cytochrome P-450 cholesterol 7 alpha-hydroxylase: inhibition of enzyme deactivation by structurally diverse calmodulin antagonists and phosphatase inhibitors. , 1987, Archives of biochemistry and biophysics.

[41]  Y. Chao,et al.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. , 1980, The Journal of biological chemistry.

[42]  M. L. Matute,et al.  Sex steroid influence on hepatic gluconeogenesis and glucogen formation. , 1973, Endocrinology.

[43]  P. Zimmet,et al.  The effect of age on glucose tolerance: Studies in the polynesian population of funafuti , 2007, Acta diabetologia latina.

[44]  Sunhyo Jeong,et al.  Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. , 2007, Obesity.

[45]  G. Gallus,et al.  Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.

[46]  E. Surmacz,et al.  Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. , 2003, Oncogene.

[47]  K. Friday,et al.  Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  A. Minnich,et al.  A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. , 2001, American journal of physiology. Endocrinology and metabolism.

[49]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[50]  T. Willson,et al.  Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. , 2001, Endocrinology.

[51]  M. Frölich,et al.  Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM , 1997, Diabetologia.